Head-to-head evidence
Apomorphine sublingual film (Kynmobi) vs LY03009
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine · full Parkinson's Disease pipeline
Apomorphine sublingual film (Kynmobi)
Marketed by Sumitomo Pharma
NCT02469090 · Phase 3 · completed
The study randomized 109 patients to apomorphine sublingual film or matching placebo in a quadruple-blind design, with 54 patients receiving apomorphine and 55 receiving placebo. The primary clinical motor-function endpoint was met: the MDS-UPDRS Part III score improved more with apomorphine than placebo at Week 12 (p=0.0002).
LY03009
Developed by Luye Pharma Group
NCT04593511 · Phase 1 · status unknown
This open-label, single-dose pharmacokinetic study compared four different formulations of LY03009 against each other in healthy volunteers, but included no placebo or inactive control arm and no blinding. No results have been posted, and because every arm receives active drug in a different formulation, this design cannot demonstrate a treatment effect once results are available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Apomorphine sublingual film (Kynmobi)'s landscape · LY03009's landscape